Application of jatrorrhizine hydrochloride in reversing drug resistance of pancreatic cancer cells

Abstract

The invention relates to the technical field of biomedicine, in particular to the application of jatrorrhizine hydrochloride in reversing the drug resistance of pancreatic cancer cells. Under the synergistic effect of said jatrorrhizine hydrochloride, gemcitabine has a more significant Reversal of the resistance of pancreatic cancer cells to gemcitabine. The present invention studies pancreatic cancer Panc-1 cells and gemcitabine drug-resistant Panc-1 cells, and finds that under the action of jatrorrhizine hydrochloride, the drug sensitivity of pancreatic cancer cells to gemcitabine is enhanced, and low concentrations of gemcitabine and jatrorrhizine hydrochloride Combined use can achieve the effect of high concentration gemcitabine on drug-resistant Panc‑1 cells, and as the concentration of jatrorrhizine hydrochloride increases, the combination with gemcitabine can effectively inhibit the growth of drug-resistant Panc‑1 cells, and its growth inhibitory effect is much higher The drug resistance of drug-resistant Panc‑1 cells to gemcitabine was significantly reversed when gemcitabine was used alone.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of jatrorrhizine hydrochloride in reversing the resistance of pancreatic cancer cells to gemcitabine. Background technique [0002] Pancreatic cancer is one of the refractory gastrointestinal tumors with relatively high malignancy, and its incidence is on the rise worldwide. Because there are usually no symptoms in the early stage, and these symptoms are usually non-specific, patients are often found when they are diagnosed. It has entered an advanced stage, the mortality rate is almost 100%, and the 5-year survival rate is less than 5%. The early diagnosis rate of pancreatic cancer is not high. Globally, pancreatic cancer ranks 12th and 7th among malignant tumors in morbidity and mortality, respectively. Data from the National Cancer Center shows that the number of pancreatic cancer cases in my country accounts for about 2.42% of the total number of maligna...

AI Technical Summary

Problems solved by technology

At present, the efficacy of gemcitabine-based first-line chemotherapy for advanced pancreatic cancer has stagnated at the plateau stage, and due to the special biological characteristics of pancreatic cancer cells, it is not very sensitive to other chemotherapy except gemcitabine. Therefore, gemcitabine is the first choice for the treatment of pancreatic cancer. The drug of choice, but in the clinical practice of pancreatic cancer, many patients have congenital or acquired chemotherapy resistance to gemcitabine, which limits the clinical application of gemcitabine and increases the difficulty of treatment

Images